Sirolimus-induced onychopathy in renal transplant recipients;Onychopathie associée au sirolimus chez les transplantés rénaux

Annales de Dermatologie et de Venereologie

Volumn 133, Issue 6-7, 2006, Pages 531-535

  Mahe E ^a,b,d   Morelon, E ^a,c   Lechaton, S ^a   Kreis, H ^a   De Prost, Y ^a   Bodemer, C ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICHAT HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING; CONTROLLED STUDY; ERYTHEMA; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKONYCHIA; MAJOR CLINICAL STUDY; MALE; NAIL BED; NAIL DISEASE; ONYCHOLYSIS; ONYCHOMALACIA; ONYCHORREXIS; PYOGENIC GRANULOMA; SEX RATIO; VASCULAR DISEASE;

EID: 33746874401     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(06)70957-7     Document Type: Article

References (29)

1. Piraccini BM, Lorizzo M, Antonucci A, Tosti A. Drug-induced nail abnormalities. Expert Opin Drug Saf 2004;3:57.
2. Mahé E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005;79:476-82.
3. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3-16.
4. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005;28:153-81.
5. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23.
6. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-42.
7. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
8. MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003;35:S201-8.
9. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003;35:S52-7.
10. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004;15:809-17.
11. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001;145:438-45.
12. Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005;52 (2 Suppl 1):17-9.
13. Van Gelder T, ter Meulen CG, Hene R, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75:788-91.
14. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid oedema in kidney transplant recipients. Transplantation 2001;72:162-4.
15. Aboujaoude W, Milgrom ML, Govani MV. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 2004;77:1094-6.
16. Wadei H, Gruber SA, El-Amm JM, Garnick J, West MS, Granger DK, et al. Sirolimus-induced angioedema. Am J Transplant 2004;4:1002-5.
17. Burdese M, Rossetti M, Guarena C, Consiglio V, Mezza E, Soragna G, et al. Sirolimus and ACE-inhibitors: a note of caution. Transplantation 2005;79:251-2.
18. Stallone G, Infante B, Di Paolo S, Schena A, Grandaliano G, Gesualdo L, et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004;19:2906-8.
19. Saray Y, Seckin D, Gulec AT, Akgun S, Haberal M. Nail disorders in hemodialysis patients and renal transplant recipients: a case-control study. J Am Acad Dermatol 2004;50:197-202.
20. Rault R. Mycophenolate-associated onycholysis. Ann Intern Med 2000;133:921.
21. Baran R, Juhlin L. Drug-induced photo-onycholysis. Three subtypes identified in a study of 15 cases. J Am Acad Dermatol 1987;17:1012-6.
22. Baran R. Retinoids and the nails. J Dermatol Treat 1990;1:151-4.
23. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742-8.
24. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.
25. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-6.
26. Boucher KW, Davidson K, Mirakhur B, Goldberg J, Heymann WR. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002;47:632-3.
27. Nakano J, Nakamura M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol 2003;30:261-2.
28. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:225-6.
29. Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004;9:406-9.